Hereditary Hemorrhagic Telangiectasia Clinical Trials

Find Hereditary Hemorrhagic Telangiectasia Clinical Trials Near You

Health-Related Quality of Life and Clinical Utilization in Pediatric and Young Adult Patients With Hereditary Hemorrhagic Telangiectasia

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT). Eligible participants are patients receiving care at Cincinnati Children's Hospital Medical Center and / or their caregivers. Participants will complete validated quality-of-life questionnaires assessing physical, emotional, social, and disease-specific functioning over the past 30 days. A paired retrospective chart review will assess disease severity and clinical utilization, including procedures and imaging studies. The primary objective is to describe mean QoL scores for this population. Secondary objectives include evaluating associations between QoL scores, disease severity, and clinical utilization.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 25
Healthy Volunteers: f
View:

• • Patient aged 2-25 years with a confirmed (either genetic or clinical) diagnosis of definite HHT

‣ Parent or legal guardian willing and able to complete the caregiver survey for patients aged 2-17.

⁃ For patients \>18, willing and able to complete the patient survey.

⁃ Receipt of care through CCHMC (at least one visit with genetic counselor or director of HHT Center)

⁃ Ability to complete survey in English

⁃ For self-report: patient age greater than or equal to 8 years old that assent to survey.

Locations
United States
Ohio
Cincinnati Children's Hospital Medical Center
RECRUITING
Cincinnati
Contact Information
Primary
Katie Wusik, Master of Genetic Counseling
katie.wusik@cchmc.org
(513) 636-3200
Backup
Ashley Nelson
ashley.nelson@cchmc.org
Time Frame
Start Date: 2026-09-01
Estimated Completion Date: 2027-08
Participants
Target number of participants: 70
Sponsors
Leads: Ashley Nelson

This content was sourced from clinicaltrials.gov